Oramed Pharmaceuticals has been give the green light to begin clinical trials in South Africa, and the researchers are very optimistic.
Oramed CEO Nadav Kidron, in an interview with i24 News, offers several reasons why his company’s development of an oral vaccine against COVID-19 could be the key to increasing vaccination rates around the world.
“We are very excited,” he said, explaining that it would be a “one-time shop,” as the pill would protect against all existing and future variants.
“We want to make sure we can get emergency-use approval as soon as possible,” he told i24 News. “We are very excited.”